search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Beweegkuur +.


- candidate number8331
- NTR NumberNTR2464
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR11-aug-2010
- Secondary IDsMEC-2010-154 METC Erasmus MC
- Public TitleBeweegkuur +.
- Scientific TitleThe medium and long-term benefits of a structured rehabilitation (Beweegkuur+) program in long-standing type 2 diabetes patients with multiple disabling co-morbidities.
- ACRONYM
- hypothesisBecause of the high cardiovascular risk profile and functional disabilities of obese long-standing type 2 diabetes patients, therapeutic exercise programs have hardly been evaluated in this subpopulation. The current research proposal aims to investigate the medium and long-term health benefits of a combined supervised exercise and dietary intervention versus a dietary intervention (=usual care) in obese long-standing type 2 diabetes patients. It is hypothesized that supervised exercise training combined with dietary measures will improve muscle strength cardiorespiratory fitness and body composition. The latter will improve both physical and mental health status, resulting in improved metabolic control through a durable increase in total weekly energy expenditure.
- Healt Condition(s) or Problem(s) studiedDiabetes Mellitus Type 2 (DM type II)
- Inclusion criteria1. Type 2 diabetes > 5 years;
2. Signs of 3 or more diabetes¨Crelated co-morbidities (history of sensori-motor or autonomic neuropathy,retinopathy (gr II or higher), micro-albuminuria, coronary artery disease, transient ischaemic attack, intermittent claudication/peripheral artery disease);
3. HbA1c: 7.0- 10.0%;
4. Age: 45-75 yrs;
5. BMI > 27kg/m2;
6. Sedentary behaviour (i.e. <30 min/day moderately active assessed by activity monitoring);
7. Agreement to volunteer for the study by giving a written informed consent.
- Exclusion criteria1. Cardio-vascular disease, recent (< 3 m) decompensatio cordis, recent (3 m) unstabile angina pectoris, recent (< 3 m) myocardial infarction, significant cardiac ischaemia during SPECT myocardial perfusion imaging, heartfailure (EF<40% or NYHA class 3 or 4);
2. Severe orthopaedic impairments that would prohibit participation in the training program (eg diabetes ulcers of the foot, amputations);
3. Cerebro-vascular disease (CVA) or other neurological diseases or deficits that would prohibit participation in the training program (eg spasticity).
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 10-aug-2010
- planned closingdate1-sep-2011
- Target number of participants80
- InterventionsIn case of an abnormal stress-ECG during a symptom-limited exercise test, more extensive cardiovascular screening (stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging) left ventricular diastolic function using echocardiography will take place by a cardiologist. Patients will be randomized to follow either a 26 weeks combined supervised exercise and dietary intervention program or to take part in a dietary intervention program aimed at decreasing daily energy intake with 600 kcal/day. Before and after 26 and 52 weeks, blood samples (HbA1c, plasma glucose, plasma insulin, HDL-C, LDL-C, TChol, Triglycerides and FFA, both during fasting conditions) and questionnaires will be collected to assess changes in glycemic control, lipid profile, health-related quality of life (Short-Form 36 questionnaire health survey), diabetes burden (revised version of the Type 2 Diabetes Symptom Checklist) and depression scores (20-item Centre for Epidemiologic Studies Depression Scale), respectively. Accelerometry based activity monitors (Actigraph) and personal exercise diaries, will be used to assess changes in daily physical activity levels. Changes in regional body composition, functional capacity, muscle strength and cardiorespiratory fitness will be assessed using respectively DEXA-scan and skinfold measurements, functional tests (Sit-to-Stand, 6 minute walking test), isokinetic testing and cycle-ergometry protocol.
- Primary outcomeThe primary outcome measure evaluates the clinical efficacy of the intervention on the standard diabetes outcome parameter for glycemic control (HbA1c).
- Secondary outcomeThe secondary diabetes related outcome measures evaluate the overall effect on health:
1. Risk profile for cardiovascular disease (lipid profile, arterial blood pressure, heart rate variability);
2. Body composition (BMI, waist circumference, regional fat distribution);
3. Cardiorespiratory fitness (VO2peak);
4. Left ventrical diastolic function (echocardiography);
5. Functional capacity and muscle strength;
6. Health-related quality of life (SF-36);
7. Level of depressive symptoms using the Centre for Epidemiologic Studies Depression Scale (CES-D);
8. Diabetes symptom distress (using the revised version of the Type 2 Diabetes Symptom Checklist).
- TimepointsTesting procedures will take placebefore and 26 and 52 weeks following the start of the exercise intervention.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES D. Visser
- CONTACT for SCIENTIFIC QUERIESDr. S.F.E. Praet
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development, Nederlands Instituut voor Sport en Beweging (NISB)
- PublicationsN/A
- Brief summaryBecause of the high cardiovascular risk profile and functional disabilities of obese long-standing type 2 diabetes patients, therapeutic exercise programs have hardly been evaluated in this subpopulation. The current research proposal aims to investigate the medium and long-term health benefits of a combined supervised exercise and dietary intervention versus a dietary intervention (=usual care) in obese long-standing type 2 diabetes patients. It is hypothesized that supervised exercise training combined with dietary measures will improve muscle strength cardiorespiratory fitness and body composition. The latter will improve both physical and mental health status, resulting in improved metabolic control through a durable increase in total weekly energy expenditure.

Intervention group:
In addition to the protocolised diabetes care offered at the Diabetes Plein at Erasmus University Medical Centre (usual care), 40 type 2 diabetes patients randomized for the exercise and dietary intervention will be invited for an intake with a sport and exercise/rehabilitation physician and a physical therapist. Subsequently they will be asked to adhere to 26 weeks of once a week progressive resistant type of exercise, supplemented by short bouts of high intensity interval endurance training. Subjects can choose from 4 possible training locations.

Control group:
The 40 patients randomized to the control group will have 3-monthly motivational interviews with a lifestyle coach/nurse practitioner in addition to the protocolised diabetes care offered at the Diabetes Plein (usual care) or their general practitioner. During these interviews patients will get practical advices on how to increase physical exercise level, based on the results from the baseline physical activity monitoring and personal exercise diaries. Furthermore, they will consult a dietician on a monthly basis during the first 6 months to guide and support patients in an energy intake restriction diet (-600 kcal/day) aimed at a weight reduction of 5-10% over 6 months.

Testing procedures before and 26 and 52 weeks following the start of the exercise intervention:
1. Before final inclusion all patients will undergo a symptom limited cycle ergometry test with 12 lead ECG monitoring. In case silent myocardial ischaemia is suspected [58], patients will be referred to a cardiologist to assess myocardial perfusion with a stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging;
2. Furthermore, at the beginning and 26 and 52 weeks following the exercise intervention, left ventricular diastolic function will be monitored using echocardiography;
3. Fasting blood samples will be obtained to measure HbA1c, plasma glucose, plasma insulin, HDL-C, LDL-C, T-Chol, Triglycerides and FFA, both during fasting conditions;
4. Subjects will be asked to fill out a 3-day dietary record both before as well as 26 and 52 weeks following the start of the training program to estimate energy consumption and meal composition. The latter information will be used to provide the patient with a tailor made online advice on a healthier diet as recommended by the Dutch Diabetes Federation;
5. Accelerometry based activity monitors (Actigraph) will be worn by the patients during 7 days to assess daily energy expenditure and both In addition and personal exercise diaries, will be used to estimate leisure-time physical activity;
6. Peak whole-body oxygen uptake capacity (VO2peak) and maximal workload capacity (Wmax) will be measured during an incremental exhaustive exercise test until volitional exhaustion, performed on a cycle ergometer using a ramp protocol. Gas exchange measurements will be performed continuously. During exercise testing a 12-lead electrocardiogram will be monitored and recorded. Because the exercise test will be executed in a hospital setting with ECG monitoring and direct supervision of a physician, the risk of cardiac ischemia/arritmia is small. If a hypoglycemic event occurs, there will carbohydrate solutions or, in case of loss of consciousness, Glucagon (Glycagen, 1 mg dissolved in 1 ml) are available;
7. Isokinetic strength testing will be used to measure muscle strength and resistance to fatigue of the upper arm and leg muscles;
8. To test improvements in functional capacity a standardized Sit-to-Stand as well as a steep ramp test on a cycle ergometer will be performed;
9. Resting blood pressure will be measured twice during 15 min supine position using an automatic blood pressure measuring device. Simultaneously a continuous heart rate monitor will be used to measure heart rate variability as a validated measure for autonomic dysregulation;
10. Dual Energy X-ray Absorptiometry (DEXA) will be used to monitor regional changes in body composition (trunk vs legs) and fat percentage;
11. Health related quality of life will be measured using the Short-Form 36 questionnaire health survey. Levels of depressive symptoms will be measured using the 20-item Centre for Epidemiologic Studies Depression Scale (CES-D score ≥ 16). To measure diabetes symptom distress, we will use the revised version of the Type 2 Diabetes Symptom Checklist.
- Main changes (audit trail)
- RECORD11-aug-2010 - 23-aug-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl